+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Off-label reports of new biologics: exciting new therapy or dubious research? Examples from recombinant activated factor VII



Off-label reports of new biologics: exciting new therapy or dubious research? Examples from recombinant activated factor VII



Journal of Intensive Care Medicine 21(4): 247-248




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 049744860

Download citation: RISBibTeXText

PMID: 16855060

DOI: 10.1177/0885066606288844


Related references

Off-label Reports of New Biologics: Exciting New Therapy or Dubious Research? Examples From Recombinant Activated Factor Vii. Journal of Intensive Care Medicine 21(1): 54-59, 2006

Use of Low-Dose Recombinant Activated Factor VII in the Off-Label Setting: A Comment to "The Judicious Use of Recombinant Factor VIIa". Seminars in Thrombosis and Hemostasis: -, 2016

On-label versus off-label use of recombinant activated factor VII: a comprehensive review of use in two Canadian centers. Seminars in Hematology 45(2 Suppl 1): S68-S71, 2008

Off-label use of recombinant activated factor VII in children. Blood 102(11): 137b, 2003

Off label use of recombinant activated factor VII: a practice survey. Annales Francaises d'Anesthesie et de Reanimation 26(9): 774-779, 2007

Off-Label Use of Recombinant Activated Factor VII for Enucleation Following Eye Trauma. Blood 100(11): Abstract No 3910, 2002

Emerging off-label uses for recombinant activated factor VII: grading the evidence. Critical Care Clinics 21(3): 611-632, 2005

Off-label use of recombinant activated factor VII for bleeding following a percutaneous liver biopsy. Vox Sanguinis 83(Suppl. 2): 58-59, 2002

Evaluation of off-label recombinant activated factor VII for multiple indications in children. Clinical and Applied Thrombosis/Hemostasis 13(3): 233-240, 2007

Off-label use of recombinant activated factor VII for massive bleeding in trauma and surgery. Vox Sanguinis 83(Suppl. 2): 59, 2002

Controlled off-label use of recombinant activated factor VII (NovoSeven) can build evidence base. Cardiovascular Journal of Africa 19(1): 52-54, 2008

"Evaluation of off-label recombinant activated factor VII for multiple indications in children" by Reiter et al. Clinical and Applied Thrombosis/Hemostasis 14(2): 247; Author Reply 247, 2008

Comprehensive Canadian review of the off-label use of recombinant activated factor VII in cardiac surgery. Circulation 118(4): 331-338, 2008

Setting the Bar Higher For Off-Label Use of Biologics: Off-label use of biologics is common as physicians strive for optimal treatment. Patients want whatever works. Drug makers want expanded labeling, but payers chafe at the lack of efficacy data. Is there an answer to this conundrum?. Biotechnology Healthcare 8(3): 14-18, 2011

A review of the off-label use of recombinant activated factor VII in a developing country tertiary care center. Blood Coagulation and Fibrinolysis 17(8): 647-650, 2006